Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: In systemic sclerosis (SSc), gastrointestinal involvement is one of the earliest events. We compared the gut microbiota (GM), its short-chain fatty acids (SCFAs) and host-derived free fatty acids (FFAs) in patients with very early diagnosis of SSc (VEDOSS) and definite SSc.

Methods: Stool samples of 26 patients with SSc, 18 patients with VEDOSS and 20 healthy controls (HC) were collected. The GM was assessed through 16S rRNA sequencing, while SCFAs and FFAs were assessed by gas chromatography-mass spectrometry.

Results: In patients with VEDOSS, an increase in Bacteroidales and Oscillospirales orders and a decrease in Bacilli class, and genera was detected in comparison with HC. In patients with SSc, an elevated number of Acidaminococcaceae and Sutterellaceae families, along with a decrease of the Peptostreptococcaceae family and and genera was found in comparison with HC. Patients with SSc and VEDOSS had a significantly lower butyrate and higher acetate with respect to HC. In VEDOSS, an increase in Oscillospiraceae family and genus, and a decrease in class, and Lactobacillales order was identified with respect to SSc. Moreover, patients with VEDOSS exhibited higher acetate and lower valerate compared with definite SSc.

Conclusion: A GM dysbiosis with depletion of beneficial anti-inflammatory bacteria (especially butyrate-producing) and a significant decrease in faecal butyrate was identified in patients with VEDOSS. This early GM imbalance may foster the growth of inflammatory microbes, worsening intestinal dysbiosis and inflammation in early SSc stages. The potential butyrate administration in early disease phases might be considered as a novel therapeutic approach to mitigate gastrointestinal discomfort and progression preserving patient's quality of life.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574430PMC
http://dx.doi.org/10.1136/rmdopen-2024-004647DOI Listing

Publication Analysis

Top Keywords

patients vedoss
16
patients ssc
12
gut microbiota
8
systemic sclerosis
8
fatty acids
8
patients
8
ssc vedoss
8
ssc patients
8
vedoss increase
8
comparison patients
8

Similar Publications

Objectives: To describe the prevalence of gastrointestinal (GI) symptoms in systemic sclerosis (SSc) and Very Early Diagnosis of SSc (VEDOSS), identify clinical and serological features associated with GI involvement, and explore a cranio-caudal pattern of symptom distribution, using data from the Italian SPRING-SIR registry.

Methods: This cross-sectional analysis included patients fulfilling 2013 ACR/EULAR SSc or VEDOSS criteria. GI involvement was defined as symptoms in at least one GI tract segment and categorized as upper and lower.

View Article and Find Full Text PDF

Systemic sclerosis (SSc) frequently affects hands, impairing its function and impacting quality of life. The ABILHAND-SSc is a patient-reported outcome measure (PROM) specifically designed to assess manual ability in SSc. Previously, an European Portuguese version has been translated and culturally adapted, but its psychometric properties remain to be validated.

View Article and Find Full Text PDF

Background: Interleukin 40 (IL-40) is a cytokine implicated in malignancies and rheumatic disorders. Its association with fibrotic mediators has been previously described. Since inflammation and fibrosis are hallmarks of systemic sclerosis (SSc), we aimed to analyze the role of IL-40 in SSc.

View Article and Find Full Text PDF

Objectives: To analyse clinical features and biomarkers associated with primary heart involvement (pHI) confirmed at cardiac magnetic resonance (CMR) in a monocentric cohort of SSc patients.

Methods: A retrospective study. SSc patients who underwent CMR for clinically suspected pHI were identified.

View Article and Find Full Text PDF

Introduction: Introduction: Interstitial lung involvement (ILD) is one of the main complications in patients with systemic sclerosis (SSc), representing a significant cause of mortality. According to previous reports, ILD can appear in many patients from early stages (eSSc) to patients with established disease without skin involvement (ssSSc).

Methods: Patients were included in the ssSSc group if they met the ACR/EULAR 2013 classification criteria and had a Rodnan skin score 0.

View Article and Find Full Text PDF